期刊文献+

抗血小板治疗的最新进展 被引量:14

The Latest Progress of Antiplatelet Therapy
下载PDF
导出
摘要 大量临床研究已证实抗血小板药物:阿司匹林、噻吩吡啶类药物、血小板膜糖蛋白受体拮抗剂、西洛他唑等在预防和治疗心脑血管疾病以及外周动脉血管病变中具有十分重要的作用。洞悉药物的作用机理、应用现状、进展和存在的争议,对于更好地运用该类药物具有十分重要的作用。现就相关内容进行简要综述。 Many clinical studies have confirmed that antiplatelet drugs act important roles to prevent and treat the cardiac disease, cerebrovascular disease and peripherial artery disease, such as aspirin, thienopyridine, GPⅡ b/ Ⅲa receptor antagonist, cilostazol and so on. In order to make use of these drugs better, it is very important that to know clearly their mechanism of action, the current situation of application, advancement and the dispute. This article provides an overview on these questions.
出处 《心血管病学进展》 CAS 2009年第1期102-105,共4页 Advances in Cardiovascular Diseases
关键词 抗血小板药物 阿司匹林 噻吩吡啶类药 血小板膜糖蛋白受体拮抗剂 西洛他唑 普拉格雷 antiplatelet drugs aspirin thienopyridine GP Ⅱ b/ Ⅲ a receptor antagonist cilostazol prasugrel
  • 相关文献

参考文献14

  • 1CAPRIE Steering Committee. A randomized, blinded trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) [ J ]. Lancet, 1996, 348: 1329-1339.
  • 2Yusuf S,Zhao F,Mehta SR,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [ J ]. N Engl J Med,2001,345: 494-502.
  • 3Peters R J, Mehta SR, Fox KA, et ah Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study[J].Circulation,2003,108: 1682-1687.
  • 4Wiviot SD, Trenk D, Frellnger AL. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention [ J ]. Circulation,2007,116:2923 -2932.
  • 5Ishii H, Kumada Y,Toriyama T. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease[J]. Clin J Am Soc Nephrol,2008,3(4) :1034-1040.
  • 6Hiatt WR,Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects) [J]. J Vase Surg,2008,47(2) :330-336.
  • 7Douglas JS Jr, Holmes DR Jr, Kereiakes DJ. Coronary stent restenosis in patients treated with cilostazol[ J]. Circulation,2005,112(18) :2759-2761.
  • 8Zhang Z, Foster JK, Kolm P. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial [ J ]. Am Heart J, 2006,152 (4) :770-776.
  • 9Wiviott SD, Antman EM,Winters KJ,et al. Randomized comparison of prasugrel ( CS-747, LY640315 ), a novel thienopyridine P2 Y 12 antagonist, with clopidogrel in percutaneous coronary intervention [ J ]. Circulation,2005, 111:3366-3373.
  • 10Wiviott SD ,Trenk D,Frelinger AL. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention : the prasugrel in comparison to clopidogrel for inhibition of platelet aclivation and aggregation-thrombolysis in myocardial infarction 44 trial [ J ]. Circulation,2007,116 ( 25 ) :2923 -2932.

同被引文献141

引证文献14

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部